KRYS - Krystal Biotech, Inc.
| Previous Close | 20.66 |
| Open | 21.71 |
| Bid | 22.27 x 800 |
| Ask | 22.30 x 900 |
| Day's Range | 21.13 - 22.57 |
| 52 Week Range | 8.03 - 24.89 |
| Volume | 731,928 |
| Avg. Volume | 57,624 |
| Market Cap | 245.708M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.50 |
- GlobeNewswire•19 hours ago
Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the previously announced underwritten public offering of 3,000,000 shares of its common stock, at a public offering price of $20.00 per share. The Company granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock. The gross proceeds to the Company from this offering are expected to be approximately $60.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.
- GlobeNewswire•2 days ago
Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock
Krystal Biotech, Inc. (KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has commenced an underwritten public offering of $60.0 million of its common stock. The Company intends to grant the underwriters a 30-day option to purchase additional $9.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- GlobeNewswire•4 days ago
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
KB103 is Krystal’s first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa. Results on 2 patients met all primary efficacy (presence of functional COL7 expression, observation of NC1 and NC2 reactive anchoring fibrils and continued expression following repeat administration) and safety endpoints (no adverse events, inflammation or irritation) in topically administered KB103 wounds.
- GlobeNewswire•15 days ago
Krystal Biotech to Present at Chardan Annual Genetic Medicines Conference
PITTSBURGH, Oct. 04, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.
- GlobeNewswire•18 days ago
Krystal Biotech to Present at 2018 Cell & Gene Meeting on the Mesa
PITTSBURGH, Oct. 01, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Suma ...
- GlobeNewswire•24 days ago
Krystal Biotech to Present at Upcoming Cantor Fitzgerald and Ladenburg Thalmann Conferences
PITTSBURGH, Sept. 25, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish ...
- GlobeNewswire•2 months ago
Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences
PITTSBURGH, Aug. 29, 2018-- Krystal Biotech Inc.,, a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish ...
- GlobeNewswire•2 months ago
Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis
Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation (“RPDD”) to the company’s gene therapy candidate KB105, for the treatment of patients with TGM-1-deficient autosomal recessive congenital ichthyosis (“ARCI”).
- PR Newswire•2 months ago
Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase
NEW YORK , Aug. 17, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as sole placement agent in Krystal Biotech, Inc.'s (NASDAQ: KRYS) securities purchase agreement ...
- GlobeNewswire•2 months ago
Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners
Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million and is expected to close on August 17, 2018, subject to the satisfaction of customary closing conditions. “We are extremely pleased that an impressive investor like Frazier Healthcare Partners supports our efforts to become a leader in the field of dermatological diseases,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc.
- GlobeNewswire•2 months ago
Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis
Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s second product candidate, KB105, currently in preclinical development for treatment of patients with transglutaminase 1 (TGM-1) deficient autosomal recessive congenital ichthyosis (“ARCI”). “We are pleased to receive Orphan Drug Designation for KB105 to treat ARCI as this is an important step forward in our efforts to bring hope to ARCI patients and their families," said Suma M. Krishnan, founder and chief operating officer of Krystal Biotech. “We are excited by the results of the pharmacology data in animal models to date for ARCI that we submitted to the Office of Orphan Product Development.
- GlobeNewswire•2 months ago
Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Commenting on second quarter results, Krish S. Krishnan, chairman and chief executive officer of Krystal Biotech, said, “2018 is a year of execution for Krystal as we strive to achieve three important value-creating catalysts. First and foremost, in the clinic, we intend to announce interim safety and efficacy results from the KB103 Phase 1/2 study for the treatment of dystrophic epidermolysis bullosa (DEB) by Q4 2018.
- Zacks•3 months ago
Krystal Biotech (KRYS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
- Zacks•4 months ago
Can the Rally in Krystal Biotech (KRYS) Shares Continue?
Krystal Biotech, Inc. (KRYS) has been on the move lately as the stock has risen by 24.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
- ACCESSWIRE•5 months ago
Blog Exposure - Krystal Biotech’s KB103 Granted Fast Track Designation by FDA for Treatment of Dystrophic Epidermolysis Bullosa
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) ("Krystal"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On May 24, 2018, the Pennsylvania-based Company announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead product, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever topically-applied herpes simplex virus (HSV-1) based gene therapy engineered to deliver a human collagen protein to patients suffering from DEB.
- ACCESSWIRE•6 months ago
Wired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe
LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Krystal Biotech, Inc. (NASDAQ: KRYS) (''Krystal''). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KRYS as the Company's latest news hit the wire. On April 19, 2018, the Company announced that the European Medicines Agency (EMA) granted the Orphan Medicinal Product Designation (OMPD) for its lead product KB103, a gene therapy candidate for the treatment of Dystrophic Epidermolysis Bullosa (DEB).
